ALK-001

The dry age-related macular degeneration (AMD) therapeutic landscape is robust, with over 70 companies developing more than 80 therapies.

Alkeus Pharmaceuticals shared results from TEASE studies, showing that gildeuretinol (ALK-001) significantly reduced the growth rate of retinal atrophic lesions in Stargardt disease patients.

Gildeuretinol (ALK-001) received Rare Pediatric Disease and Fast Track Designations from the FDA for Stargardt disease treatment.

Gildeuretinol (ALK-001), an oral vitamin A-derived drug, significantly reduced the growth of atrophic retinal lesions in Stargardt disease patients by 21% compared to placebo.

Alkeus Pharmaceuticals' oral gildeuretinol acetate (ALK-001) did not meet the primary endpoint of reducing geographic atrophy (GA) lesion growth rate in the SAGA phase 3 study.